Merck is acquiring Verona Pharma for $10 billion, gaining COPD drug Ohtuvayre as part of its strategy to offset Keytruda’s looming patent loss.
Merck is acquiring Verona Pharma for $10 billion, gaining COPD drug Ohtuvayre as part of its strategy to offset Keytruda’s looming patent loss.